A Phase IB Study of Crizotinib (XALKORI) and Sunitinib (SUTENT) in Metastatic Breast Cancer
Phase of Trial: Phase I
Latest Information Update: 11 Aug 2017
Price : $35 *
At a glance
- Drugs Crizotinib (Primary) ; Sunitinib (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions
- Acronyms CRIZENT
- 08 Aug 2017 Status changed from recruiting to discontinued due to poor accrual.
- 23 Aug 2016 Planned End Date changed from 1 Jun 2016 to 1 Aug 2018.
- 23 Aug 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Aug 2018.